Zolpidem drug data and news

---

Neurocrine Shares Dumped As FDA Sets Back Indiplon  17 May 2006
The insomnia space is led by immediate- and extended-release versions of Ambien (zolpidem), a blockbuster product from Paris-based Sanofi-Aventis Group. ... - BioWorld Online (subscription),

sanofi-aventis reiterates safety of zolpidem tartrate CIV as ...  Apr 19, 2006
2006 APR 19 - (NewsRx.com) -- sanofi-aventis (SNY) reports that Ambien (zolpidem tartrate) CIV, when taken as directed, provides a safe and effective treatment ... - Therapeutics Daily (subscription) (press release),

There's more to falling asleep than just counting sheep  May 15, 2006
RECENT news stories about the troubles of a well-known congressman mentioned the sleep disorder drug Ambien (zolpidem tartrate). ... - Inside Bay Area,

Snooze alarm: The pill that drove us to sleep  May 6, 2006
WASHINGTON - Zolpidem tartrate, the sedative-hypnotic better known to wide-awake, stressed-out sheet kickers as Ambien, is an efficacious little helper if you ... - Standard-Speaker,

Patrick Kennedy's Psychedelic Freak Out!  May 5, 2006
...opoids. But the reason for my post is to explain what happens to me when I mix phenergan with Ambien or Sonata (zolpidem or zaleplon). ... - Yahoo! News

ReGen Therapeutics Plc - Issue of Equity  May 12, 2006
Executive Chairman Percy Lomax commented, 'The capital raised will be used to fund the proposed Phase IIa trials of zolpidem and development of Colostrinin(TM ... - PharmaLive.com (press release),

Kennedy crashes car into DC traffic barrier  May 4, 2006
...vision, or dry mouth. Zolpidem, the generic name for Ambien, is used to treat sleep problems, according to the Web site. It may help ... - Providence Journal (subscription),

The Pill That Drove Us to Sleep  May 5, 2006
Zolpidem tartrate, the sedative-hypnotic better known to wide-awake, stressed-out sheet kickers as Ambien, is an efficacious little helper if you ever thought ... - Washington Post,

Zentiva NV 1st Quarter Results 2006  May 2, 2006
Out of our key promoted brands good sales growth was achieved by the hypnotic drug Hypnogen (zolpidem), the anti-hypertensive product Lozap (losartan) and the ... - PharmaLive.com (press release),

No More Counting Sheep  May 3, 2006
...are Somnatrol, Dormías and RevitaSleep. Ambien and Lunesta both use a sedative/hypnotic drug called Zolpidem. It helps you fall ... - University Daily Kansan,

Ambien User Paints During Sleep; Kennedy Use of Ambien Might Have ...  May 6, 2006
...events. New York, NY (PRWEB) May 6, 2006 -- Sanofi-Aventis, is the maker of the sleep drug Ambien (trade name for zolpidem). Many ... - PR Web (press release),

Sepracor Announces First Quarter 2006 Results  Apr 25, 2006
Among study participants, the most commonly used previoustherapies were AMBIEN(R) brand zolpidem tartrate, other prescriptioninsomnia medications, and trazodone ... - Finanzen.net,

Sepracor Announces First Quarter 2006 Results  Apr 25, 2006
Among study participants, the most commonly used previous therapies were AMBIEN(R) brand zolpidem tartrate, other prescription insomnia medications, and ... - Genetic Engineering News,

New weapons in travelers' round-the-clock jet-lag fight  Apr 21, 2006
..."Ambien (zolpidem tartrate) gets you seven or eight hours of sleep," she says. "Lunesta (eszopiclone) provides seven or eight hours. ... - Los Angeles Times,

Neurocrine Biosciences Reports First Quarter 2006 Results  Apr 24, 2006
...of affinity and selectivity for alpha 1 containing GABA-A receptors compared to the currently marketed non-benzodiazepine sleep agents zolpidem (Ambien(R ... - PR Newswire (press release),

CNS-Active Drugs

Zolpidem tartrate was evaluated in healthy volunteers in single-dose interaction studies for several CNS drugs. A study involving haloperidol and zolpidem revealed no effect of haloperidol on the pharmacokinetics or pharmacodynamics of zolpidem. Imipramine in combination with zolpidem produced no pharmacokinetic interaction other a 20% decrease in peak levels of imipramine, but there was an additive effect of decreased alertness. Similarly, chlorpromazine in combination with zolpidem produced no pharmacokinetic interaction, but there was an additive effect of decreased alertness and psychomotor performance. The lack of a drug interaction following single-dose administration does not predict a lack following chronic administration.

An additive effect on psychomotor performance between alcohol and zolpidem was demonstrated.

A single-dose interaction study with zolpidem 10 mg and fluoxetine 20 mg at steady-state levels in male volunteers did not demonstrate any clinically significant pharmacokinetic or pharmacodynamic interactions. When multiple doses of zolpidem and fluoxetine at steady-state concentrations were evaluated in healthy females, the only significant change was a 17% increase in the zolpidem half-life. There was no evidence of an additive effect in psychomotor performance.

Following five consecutive nightly doses of zolpidem 10 mg in the presence of sertraline 50 mg (17 consecutive daily doses, at 7:00 am, in healthy female volunteers), zolpidem C _max was significantly higher (43%) and T _max was significantly decreased (53%). Pharmacokinetics of sertraline and N-desmethylsertraline were unaffected by zolpidem.

Since the systemic evaluation of zolpidem tartrate in combination with other CNS-active drugs have been limited, careful consideration should be given to the pharmacology of any CNS-active drug to be used with zolpidem. Any drug with CNS-depressant effects could potentially enhance the CNS- depressant effects of zolpidem.

Drugs that affect drug metabolism via cytochrome P450: A randomized, double-blind, crossover interaction study in ten healthy volunteers between itraconazole (200 mg once daily for 4 days) and a single dose of zolpidem (10 mg) given 5 hours after the last dose of itraconazole resulted in a 34% increase in AUC_0->∞ of zolpidem. There were no significant pharmacodynamic effects of zolpidem on subjective drowsiness, postural sway, or psychomotor performance.

A randomized, placebo-controlled, crossover interaction study in eight healthy female volunteers between 5 consecutive daily doses of rifampin (600 mg) and a single dose of zolpidem (20 mg) given 17 hours after the last dose of rifampin showed significant reductions of the AUC (ñ73%), C_max (ñ58%), and T_1/2 (ñ36%) of zolpidem together with significant reductions in the pharmacodynamic effects of zolpidem.

Other Drugs

A study involving cimetidine/zolpidem and ranitidine/zolpidem combinations revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of zolpidem. Zolpidem had no effect on digoxin kinetics and did not effect prothrombin time when given with warfarin in normal subjects. Zolpidem's sedative/hypnotic effect was reversed by flumazenil; however, no significant alterations in zolpidem pharmacokinetics were found.